アマンタジンの毒性ホルムズ震を模倣した尿薬用量のエスカレーション後のアマンタジンの毒性:症例報告
Akio Nakashima1,2, Motoyasu Miyazaki1,2, Katsuko Tachikawa3
1Department of Pharmacy, Fukuoka University Chikushi Hospital, Chikushino, JPN.
Cureus
|February 16, 2026
まとめ
アマンタジンの毒性は,特に腎臓機能不全の場合,震えを引き起こす可能性があります. アマンタジン濃度の測定は,腎機能障害の患者の神経毒性の診断に不可欠です.
科学分野:
- 薬理学 薬理学とは
- 神経学 神経学とは
- ネフロロジーは腎臓科です.
背景:
- アマンタジンは腎臓で排出され,腎臓機能の低下に伴い蓄積することがあります.
- アマンタジンの神経毒性は,小脳やホームズのような震えを模倣し,診断を複雑にする可能性があります.
- 腎機能不全は,標準用量でも有毒なアマンタジンの蓄積につながる可能性があります.
研究 の 目的:
- 腎機能不全患者のアマンタジン誘発性神経毒性の症例を震えとして報告する.
- 腎機能障害の患者におけるアマンタジンの血濃度のモニタリングの重要性を強調するためです.
主な方法:
- 併発性疾患を患っている69歳の男性患者の症例報告.
- 神経学的評価とホームズ震の診断.
- 薬剤師が推奨するアマンタジンの血濃度測定.
- 薬物中断後の腎機能と神経学的症状の解消のモニタリング.
主要な成果:
- 患者は進行的な震え,歩行不安定,および発動不良を呈しており,当初はホームズの震えと診断された.
- 血アマンタジン濃度は,サンプル採取が遅れたにもかかわらず,著しく上昇した (3,935 ng/mL).
- アマンタジンを中止すると,神経学的症状が徐々に解消し,腎臓機能が回復しました.
結論:
- 腎機能不全の患者で,新しい震えや歩行障害を発症した場合は,プラズマアマンタジン濃度の測定を検討する必要があります.
- このケースは,腎機能障害の文脈でアマンタジンの神経毒性の可能性を強調しています.
- アマンタジンの早期発見と中止は,症状の解消と腎機能の回復につながる可能性があります.
関連する概念動画
Parkinson's Disease: Treatment
1.2K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Drug Toxicity: Dose-Dependent Reactions
22
Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
22
Anticholinesterase Agents: Poisoning and Treatment
1.7K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.7K
Drug Toxicity: Risk factors
18
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
18
Drug toxicity: Idiosyncratic Reactions
21
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
21
Renal Failure: Dose Adjustments
502
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
502


